Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region


– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC –

Follow this link:
Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region

Related Posts